Last10K.com

Eagle Pharmaceuticals, Inc. (EGRX) SEC Filing 10-K Annual report for the fiscal year ending Sunday, December 31, 2017

Eagle Pharmaceuticals, Inc.

CIK: 827871 Ticker: EGRX

Exhibit 99.1

 

 

For Immediate Release

 

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2017 Results

 

— Record 2017 revenue of $237 million —

—Q4 2017 net income of $0.58 per diluted share and Adjusted Non-GAAP net income of $1.00 per diluted share —

— FY 2017 net income of $3.27 per diluted share and Adjusted Non-GAAP net income of $4.34 per diluted share —

— Agreed on path forward with the FDA for an additional clinical trial for RYANODEX for Exertional Heat Stroke —

 

WOODCLIFF LAKE, N.J.— February 26, 2018—Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq: EGRX) today announced its financial results for the three- and twelve-months ended December 31, 2017. Highlights of and subsequent to the fourth quarter of 2017 include:

 

Business and Recent Highlights:

 

·                 Agreed on a path forward with the FDA for RYANODEX® for EHS and plans to conduct an additional clinical trial in August 2018 during the Hajj pilgrimage, similar to the Eagle study conducted during the Hajj in 2015;

 

·                 Completed randomization of 600 subjects in the fulvestrant clinical study ahead of schedule during the first quarter of 2018;

 

·                 Filed an ANDA for Eagle’s first of two ANDA product candidates in 2018; awaiting FDA acceptance;

 

·                 Settled $48mm in potential Arsia milestone obligations in exchange for $15 million in cash, for a total investment in Eagle Biologics of $45 million.

 

Financial Highlights:

 

Fourth Quarter 2017

 

·                  Total revenue for the fourth quarter of 2017 was $46.8 million, compared to $81.1 million in the fourth quarter of 2016, which included $40 million in license and other income;

 

·                  Q4 2017 income before income tax provision was $9.9 million compared to $28.3 million in Q4 2016;

 

·                  Q4 2017 net income was $9.1 million, or $0.61 per basic and $0.58 per diluted share, compared to net income of $57.3 million, or $3.75 per basic and $3.52 per diluted share in Q4 2016;

 


The following information was filed by Eagle Pharmaceuticals, Inc. (EGRX) on Monday, February 26, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Eagle Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Eagle Pharmaceuticals, Inc..

Continue

Assess how Eagle Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Eagle Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Legal
M & A
Mgmt Change
Other
Filter Subcategory:
All
Expense
Product
Earnings
Shares
Debt
Geography
Income
Cash Flow
Other
Inside Eagle Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information Document
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Stockholders' Equity (deficit)
Consolidated Statements Of Operations
Acquisitions
Acquisitions - Narrative, Docetaxel (details)
Acquisitions (tables)
Acquisitions - Narrative, Biologics (details)
Acquisitions - Schedule Of Consideration Transferred, Biologics (details)
Acquisitions - Schedule Of Contingent Consideration Fair Value, Docetaxel (details)
Acquisitions - Schedule Of Contingent Consideration, Biologic (details)
Asset Sales
Asset Sales (details)
Balance Sheet Accounts
Balance Sheet Accounts (tables)
Balance Sheet Accounts - Accrued Expenses (details)
Balance Sheet Accounts - Prepaid And Other Current Assets (details)
Commitments
Commitments (tables)
Commitments - Future Minimum Lease Payments (details)
Common Stock And Stock-based Compensation
Common Stock And Stock-based Compensation (tables)
Common Stock And Stock-based Compensation - Fair Value Of Share Options Granted (details)
Common Stock And Stock-based Compensation - Narrative (details)
Common Stock And Stock-based Compensation - Recognized Share-based Compensation (details)
Common Stock And Stock-based Compensation - Schedule Of Common Stock Repurchase (details)
Common Stock And Stock-based Compensation - Share-based Compensation, Options (details)
Debt
Debt (details)
Debt - Schedule Of Debt Maturities (details)
Debt Debt (tables)
Income Taxes
Income Taxes - Narrative (details)
Income Taxes (tables)
Income Taxes - Deferred Income Taxes (details)
Income Taxes - Reconciliation (details)
Income Taxes - Schedule Of Income Tax (benefit) Expense (details)
Intangible Assets, Net
Intangible Assets, Net - Schedule Of Intangible Assets (details)
Intangible Assets, Net (tables)
Intangible Assets, Net - Narrative (details)
Intangible Assets, Net - Schedule Of Future Amortization Expense (details)
Inventory
Inventory (details)
Inventory (tables)
Legal Proceedings
Legal Proceedings Legal Proceedings (details)
License Agreements Of Development And Commercialization Rights
License Agreements Of Development And Commercialization Rights (details)
Organization And Business Activities
Organization And Business Activities (details)
Property And Equipment
Property And Equipment (details)
Property And Equipment (tables)
Related Party Transaction
Related Party Transaction (details)
Selected Quarterly Financial Data - Unaudited
Selected Quarterly Financial Data - Unaudited (details)
Selected Quarterly Financial Data - Unaudited (tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Common Shares Equivalents Outstanding (details)
Summary Of Significant Accounting Policies - Earnings Per Share (details)
Summary Of Significant Accounting Policies - Major Customers As A Percentage (details)
Summary Of Significant Accounting Policies - Narrative (details)
Ticker: EGRX
CIK: 827871
Form Type: 10-K Annual Report
Accession Number: 0000827871-18-000003
Submitted to the SEC: Mon Feb 26 2018 5:04:54 PM EST
Accepted by the SEC: Mon Feb 26 2018
Period: Sunday, December 31, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/egrx/0000827871-18-000003.htm